FI935175A0 - Tyrosinkinas- HER4-humanreceptor - Google Patents
Tyrosinkinas- HER4-humanreceptorInfo
- Publication number
- FI935175A0 FI935175A0 FI935175A FI935175A FI935175A0 FI 935175 A0 FI935175 A0 FI 935175A0 FI 935175 A FI935175 A FI 935175A FI 935175 A FI935175 A FI 935175A FI 935175 A0 FI935175 A0 FI 935175A0
- Authority
- FI
- Finland
- Prior art keywords
- tyrosine
- human receptor
- her4
- her4 human
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98116592A | 1992-11-24 | 1992-11-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FI935175A0 true FI935175A0 (fi) | 1993-11-22 |
| FI935175A FI935175A (fi) | 1994-05-25 |
Family
ID=25528166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI935175A FI935175A (fi) | 1992-11-24 | 1993-11-22 | Tyrosinkinas- HER4-humanreceptor |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0599274A1 (fi) |
| JP (1) | JPH07132084A (fi) |
| AU (1) | AU676502B2 (fi) |
| CA (1) | CA2103323A1 (fi) |
| FI (1) | FI935175A (fi) |
| IL (1) | IL107661A0 (fi) |
| MX (1) | MX9307317A (fi) |
| NO (1) | NO934163L (fi) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5811098A (en) * | 1992-11-24 | 1998-09-22 | Bristol-Myers Squibb Company | Antibodies to HER4, human receptor tyrosine kinase |
| WO1996002644A1 (en) * | 1994-07-20 | 1996-02-01 | Genetics Institute, Inc. | Mlk receptor tyrosine kinases |
| CA2202533A1 (en) * | 1994-10-14 | 1996-04-25 | Bristol-Myers Squibb Company | Her4 human receptor tyrosine kinase |
| AUPM959894A0 (en) * | 1994-11-22 | 1994-12-15 | Crc For Biopharmaceutical Research Pty Ltd | Fusion proteins with cytotoxic activity against cells overexpressing erbb2-4 |
| US6465623B2 (en) | 1995-05-02 | 2002-10-15 | Garvan Institute Of Medical Research | GDU, a novel signalling protein |
| AUPN274295A0 (en) * | 1995-05-02 | 1995-05-25 | Garvan Institute Of Medical Research | GDU, a novel signalling protein |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| ATE290595T1 (de) * | 1996-07-12 | 2005-03-15 | Genentech Inc | Gamma-heregulin |
| US7371376B1 (en) | 1996-10-18 | 2008-05-13 | Genentech, Inc. | Anti-ErbB2 antibodies |
| US6136558A (en) * | 1997-02-10 | 2000-10-24 | Genentech, Inc. | Heregulin variants |
| ATE427353T1 (de) | 1997-02-10 | 2009-04-15 | Genentech Inc | Heregulin varianten |
| US6777534B1 (en) | 1997-12-09 | 2004-08-17 | Children's Medical Center Corporation | Peptide antagonists of vascular endothelial growth factor |
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| US20010023241A1 (en) | 1998-02-04 | 2001-09-20 | Sliwkowski Mark X. | Use of heregulin as a growth factor |
| EP1941905A1 (en) | 1998-03-27 | 2008-07-09 | Genentech, Inc. | APO-2 Ligand-anti-her-2 antibody synergism |
| DK2283866T3 (en) | 1999-06-25 | 2015-05-18 | Genentech Inc | METHODS OF TREATMENT USING ANTI-ERBB ANTIBODY-MAYTANSINOID CONJUGATES |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| US7041292B1 (en) | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
| EP1189641B1 (en) | 1999-06-25 | 2009-07-29 | Genentech, Inc. | HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| US6927203B1 (en) | 1999-08-17 | 2005-08-09 | Purdue Research Foundation | Treatment of metastatic disease |
| JP2003516930A (ja) * | 1999-08-17 | 2003-05-20 | パーデュー・リサーチ・ファウンデーション | 転移性疾患の治療 |
| ES2330301T3 (es) | 1999-08-27 | 2009-12-09 | Genentech, Inc. | Dosificaciones para tratamiento con anticuerpos anti-erbb2. |
| ES2528794T3 (es) | 2000-04-11 | 2015-02-12 | Genentech, Inc. | Anticuerpos multivalentes y usos de los mismos |
| CN102698265A (zh) | 2000-05-19 | 2012-10-03 | 杰南技术公司 | 用于提高对ErbB 拮抗剂癌症治疗的有效应答可能性的基因检测试验 |
| US6255111B1 (en) | 2000-07-31 | 2001-07-03 | Isis Pharmaceuticals, Inc. | Antisense modulation of Her-4 expression |
| US20020119148A1 (en) | 2000-09-01 | 2002-08-29 | Gerritsen Mary E. | ErbB4 antagonists |
| PT1585966E (pt) | 2002-07-15 | 2012-02-20 | Hoffmann La Roche | Tratamento de cancro com o anticorpo anti-erbb2 rhumab 2c4 |
| KR101520209B1 (ko) | 2003-11-06 | 2015-05-13 | 시애틀 지네틱스, 인크. | 리간드에 접합될 수 있는 모노메틸발린 화합물 |
| JP4969440B2 (ja) | 2004-04-08 | 2012-07-04 | デビッド， ビー． エイガス， | 疼痛治療のためのＥｒｂＢアンタゴニスト |
| NZ551180A (en) | 2004-06-01 | 2009-10-30 | Genentech Inc | Antibody drug conjugates and methods |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| EP1791565B1 (en) | 2004-09-23 | 2016-04-20 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| US7939267B2 (en) | 2004-11-04 | 2011-05-10 | Laboratory Corporation Of America Holdings | Detection of activation of endothelial cells as surrogate marker for angiogenesis |
| EP3698807A1 (en) | 2005-01-21 | 2020-08-26 | Genentech, Inc. | Fixed dosing of her antibodies |
| AU2006216732C1 (en) | 2005-02-23 | 2017-07-20 | Genentech, Inc. | Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor |
| RU2009107494A (ru) | 2006-08-04 | 2010-09-10 | Астразенека Аб (Se) | АНТИТЕЛА К ErbB2 |
| WO2008109440A2 (en) | 2007-03-02 | 2008-09-12 | Genentech, Inc. | Predicting response to a her dimerisation inhibitor based on low her3 expression |
| WO2008154249A2 (en) | 2007-06-08 | 2008-12-18 | Genentech, Inc. | Gene expression markers of tumor resistance to her2 inhibitor treatment |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| US20110293614A1 (en) | 2008-11-25 | 2011-12-01 | Klaus Elenius | Isoform specific anti-her4 antibodies |
| ES2572728T3 (es) | 2009-03-20 | 2016-06-02 | F. Hoffmann-La Roche Ag | Anticuerpos anti-HER biespecíficos |
| JP5705836B2 (ja) | 2009-05-29 | 2015-04-22 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｈｅｒ２を発現する胃癌患者のｈｅｒ２シグナル伝達のためのモジュレーター |
| EP2507381A4 (en) | 2009-12-04 | 2016-07-20 | Hoffmann La Roche | PLURISPECIFIC ANTIBODIES, ANTIBODY ANALOGUES, COMPOSITIONS AND METHODS |
| WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
| CU24094B1 (es) | 2010-08-20 | 2015-04-29 | Novartis Ag | Anticuerpos para el receptor 3 del factor de crecimiento epidérmico(her3) |
| SG191153A1 (en) | 2010-12-23 | 2013-07-31 | Hoffmann La Roche | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
| JP6297490B2 (ja) | 2011-08-31 | 2018-03-20 | ジェネンテック， インコーポレイテッド | 診断マーカー |
| WO2013052686A1 (en) | 2011-10-04 | 2013-04-11 | Expression Pathology, Inc. | Srm/mrm assay for the receptor tyrosine-protein kinase erbb-4 protein (her4) |
| CA2857114A1 (en) | 2011-11-30 | 2013-06-06 | Genentech, Inc. | Erbb3 mutations in cancer |
| CN104159924B (zh) | 2011-12-05 | 2018-03-16 | 诺华股份有限公司 | 表皮生长因子受体3(her3)的抗体 |
| WO2013083810A1 (en) | 2011-12-09 | 2013-06-13 | F. Hoffmann-La Roche Ag | Identification of non-responders to her2 inhibitors |
| JP2015514710A (ja) | 2012-03-27 | 2015-05-21 | ジェネンテック， インコーポレイテッド | Ｈｅｒ３阻害剤に関する診断及び治療 |
| MX363188B (es) | 2012-11-30 | 2019-03-13 | Hoffmann La Roche | Identificación de pacientes con necesidad de coterapia del inhibidor de pd-l1. |
| BR112016021383A2 (pt) | 2014-03-24 | 2017-10-03 | Genentech Inc | Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo |
| ES2729202T3 (es) | 2014-07-16 | 2019-10-30 | Dana Farber Cancer Inst Inc Et Al | Inhibición de HER3 en cánceres ováricos serosos de grado bajo |
| EP3454863A1 (en) | 2016-05-10 | 2019-03-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combinations therapies for the treatment of cancer |
| CN110536969A (zh) | 2017-04-24 | 2019-12-03 | 豪夫迈·罗氏有限公司 | 跨膜或近膜域中的erbb2/her2突变 |
| EP4180061A1 (en) | 2021-11-10 | 2023-05-17 | Nerviano Medical Sciences S.r.l. | Anthracycline derivative linker reagents, antibody-drug conjugates and methods |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0474727T3 (da) * | 1989-05-19 | 1998-01-12 | Genentech Inc | HER2 ekstracellulært domæne |
| EP0444961A1 (en) * | 1990-03-02 | 1991-09-04 | Bristol-Myers Squibb Company | Her3: A novel EGF receptor homolog |
| IL101943A0 (en) * | 1991-05-24 | 1992-12-30 | Genentech Inc | Structure,production and use of heregulin |
-
1993
- 1993-11-17 CA CA002103323A patent/CA2103323A1/en not_active Abandoned
- 1993-11-18 NO NO934163A patent/NO934163L/no not_active Application Discontinuation
- 1993-11-18 IL IL10766193A patent/IL107661A0/xx unknown
- 1993-11-19 AU AU51804/93A patent/AU676502B2/en not_active Ceased
- 1993-11-22 FI FI935175A patent/FI935175A/fi not_active IP Right Cessation
- 1993-11-23 MX MX9307317A patent/MX9307317A/es unknown
- 1993-11-23 EP EP93118837A patent/EP0599274A1/en not_active Withdrawn
- 1993-11-24 JP JP5317374A patent/JPH07132084A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JPH07132084A (ja) | 1995-05-23 |
| AU5180493A (en) | 1994-06-09 |
| EP0599274A1 (en) | 1994-06-01 |
| CA2103323A1 (en) | 1994-05-25 |
| AU676502B2 (en) | 1997-03-13 |
| FI935175A (fi) | 1994-05-25 |
| NO934163L (no) | 1994-05-25 |
| NO934163D0 (no) | 1993-11-18 |
| MX9307317A (es) | 1994-06-30 |
| IL107661A0 (en) | 1994-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI935175A0 (fi) | Tyrosinkinas- HER4-humanreceptor | |
| DE69308324T2 (de) | Tomographie | |
| DE69311185T2 (de) | Verbinder | |
| DE69304176T2 (de) | Verbinder | |
| FI935768A (fi) | I fysiologisk omgivning upploesande mineralfibrer | |
| DE69320598D1 (de) | Verbinder | |
| DK36492D0 (da) | Praeparat | |
| DE69323147D1 (de) | Verbinder | |
| DE59302425D1 (de) | Zentraleinheit | |
| DE69315043D1 (de) | Verbinder | |
| DE69307754D1 (de) | Gewebe | |
| DE69328466T2 (de) | Verbinder | |
| DE69301589T2 (de) | Verbinder | |
| DE69311024D1 (de) | Verbinder | |
| DK0513574T3 (da) | Tærskebro | |
| DE69227940D1 (de) | Menschlicher Neurokinin-1-Rezeptor | |
| FI920701A (fi) | Anordning foer terapeutisk tryckbehandling | |
| DK28592D0 (da) | Monobetjent persienne | |
| DE69315304T2 (de) | Verbinder | |
| NO950806D0 (no) | Stolkonstruksjon | |
| KR940009398U (ko) | 척추 교정기 | |
| DE9212011U1 (de) | Badewanne | |
| NO914512D0 (no) | Sammenleggbar trapp | |
| FI222U1 (fi) | Haollare foer en kos juvrar | |
| BR9202839A (pt) | Sanitario seco-bason |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MA | Patent expired |